Obesity

Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.

The Canadian Obesity Society advocates for a therapeutic approach to obesity that removes stigma, focuses on individual patient goals, and favors body health over body weight.

Women, Black individuals, and adults diagnosed with overweight or obesity in more recent years were more likely to receive a referral, according to new study.

The proportion of overweight, obesity, or severe obesity increased from 38% to 45% among 4500 young people seen in a primary care network where most receive public insurance.

Obesity requires a spectrum of treatment options for effective results. Here, 3 key points to keep in mind when considering antiobesity medication for patients.

The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.

Tirzepatide was associated with reductions in body weight of up to 22.5% over 72 weeks in the global phase 3 registration trial.

Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Obesity significantly increased the risk of heart failure among women who experienced menopause at age ≥55 years in a new study.